NCT03507686View on ClinicalTrials.gov

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

June 29, 2022

Study Completion Date

June 29, 2022

Conditions
Choroideremia
Interventions
DRUG

BIIB111

Administered as specified in the treatment arm.

Trial Locations (6)

33136

Research Site, Miami

45242

Research Site, Cincinnati

72076

Research Site, Tübingen

75571

Research Site, Paris

97239

Research Site, Portland

02114

Research Site, Boston

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03507686 - A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 | Biotech Hunter | Biotech Hunter